# Safety and Efficacy of T8 on Treating Chronic Abnormal Immune Activation in HIV/AIDS Patients

> **NCT04084444** · PHASE2 · COMPLETED · sponsor: **Shanghai Pharmaceuticals Holding Co., Ltd** · enrollment: 151 (actual)

## Conditions studied

- Chronic Abnormal Immune Activation in HIV/AIDS

## Interventions

- **DRUG:** T8 tablet 0.5mg
- **DRUG:** T8 tablet 1mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04084444
- **Lead sponsor:** Shanghai Pharmaceuticals Holding Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-25
- **Primary completion:** 2022-07-05
- **Final completion:** 2022-07-05
- **Target enrollment:** 151 (ACTUAL)
- **Last updated:** 2023-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04084444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04084444, "Safety and Efficacy of T8 on Treating Chronic Abnormal Immune Activation in HIV/AIDS Patients". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT04084444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*